ET190L1 ARTEMIS™ T cells

BIOLOGICAL2 trials

Sponsors

Eureka Therapeutics Inc.

Conditions

Lymphoma, B-CellLymphomas Non-Hodgkin's B-Cell

Phase 1

Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

TerminatedNCT03379493

Eureka Therapeutics Inc.Lymphomas Non-Hodgkin's B-Cell

Start: 2018-04-04End: 2019-01-30Updated: 2019-02-04

Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma

CompletedNCT03415399

Eureka Therapeutics Inc.Lymphoma, B-Cell

Start: 2017-09-09End: 2020-12-31Updated: 2021-03-16

Related Papers

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma.

2023-01-2121 citations